Zang et al. showed that vildagliptin (dipeptidyl peptidase 4 inhibitor) attenuated endothelial dysfunction in diabetic rats by inhibiting the expression of miR-134-5p that stimulates BDNF and regulates endothelial function [24]. The gene discussed is DPP4; the disease is endothelial dysfunction.